An IPO for the health care business of Munich, Germany-based Siemens AG has been a long-time coming. Almost three years ago in May 2014, the German conglomerate laid out a five year plan to get it through 2020. That's when it first said it would separately manage its health care business, which was subsequently, but perhaps not eloquently, renamed Siemens Healthineers AG in May 2016. Read More
The FDA has granted de novo approval to 23andme Inc. for its report on BRCA1 and BRCA2 risk for developing breast, prostate or ovarian cancer. The direct-to-consumer (DTC) saliva test can provide insight on three genetic mutations linked to the cancers, most commonly found in patients of Eastern European, or Ashkenazi Jewish heritage, which account for a relatively small portion of patients. There are more than 1,000 mutations of the BRCA gene, and the test is not intended to diagnose or rule out the presence of mutation, or increased risk of the particular cancers due to other factors. Read More
